RDPAC: CRO Output Of China Will Double To RMB 11 Billion By 2015
This article was originally published in PharmAsia News
Executive Summary
In its research report on innovation enhancement in China’s pharma industry released on Dec. 2, the R&D-based Pharmaceutical Association Committee (RDPAC) predicted that the country’s CRO (contract research organization) sector output will double to RMB 11 billion by 2015.